Lenacapavir (Sunlenca) vs VH4004280 (VH-280)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Lenacapavir (Sunlenca)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT04143594 · Phase 2 · completed

The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.

Next expected readout: March 2027 · NCT06749054 (registry estimate)

Reported efficacy

Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants (met)

Result source: NCT04150068

VH4004280 (VH-280)

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.

Reported efficacy

Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11); Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) (unclear)

Result source: NCT06039579

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLenacapavir (Sunlenca)VH4004280 (VH-280)
HIV-1 RNA below 50 copies/mL (week 48)90.4% vs 92%vs B/F/TAFwk 54 · n 52NCT04143594
11 other results
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not reported
CD4 count, change (week 48)275 vs 248vs B/F/TAFwk 80 · n 48NCT04143594
11 other results
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Lenacapavir (Sunlenca)
90.4% vs 92%vs B/F/TAFwk 54 · n 52NCT04143594
11 other results
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
VH4004280 (VH-280)
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Lenacapavir (Sunlenca)
—Trial running · NCT06532656
VH4004280 (VH-280)
—Not reported

CD4 count, change (week 48)

Lenacapavir (Sunlenca)
275 vs 248vs B/F/TAFwk 80 · n 48NCT04143594
11 other results
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
VH4004280 (VH-280)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lenacapavir (Sunlenca): 4 of 4 rows · VH4004280 (VH-280): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenacapavir (Sunlenca)VH4004280 (VH-280)
Dropout rate
21.2%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
16.7%750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7%450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
14.3%150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%Dose Level 1b
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
14.3%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Discontinued due to AEs
1.9%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
—750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—Dose Level 1b
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—900 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—350 mg
NCT05163522 · Phase 1 · monotherapy
—250 mg + Midazolam
NCT05163522 · Phase 1 · combination
—150 mg
NCT05163522 · Phase 1 · monotherapy
—100 mg
NCT05163522 · Phase 1 · monotherapy
—50 mg
NCT05163522 · Phase 1 · monotherapy
—10 mg
NCT05163522 · Phase 1 · monotherapy
Serious AEs
7.7%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
0%750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7%450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—Dose Level 1b
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
0%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Most frequent reported AEs
a
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · combination
show 7 more results
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · combination
750 mg
injection site pain 80% (placebo 30%)
injection site erythema 40% (placebo 10%)
injection site nodule 40% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence
450 mg
injection site pain 66.7% (placebo 30%)
upper respiratory tract infection 66.7% (placebo 0%)
injection site erythema 33.3% (placebo 10%)
NCT03739866 · Phase 1 · registry result, not featured evidence
150 mg
injection site erythema 66.7% (placebo 10%)
injection site pain 66.7% (placebo 30%)
injection site induration 50% (placebo 10%)
NCT03739866 · Phase 1 · registry result, not featured evidence
50 mg
injection site pain 66.7% (placebo 30%)
syphilis 33.3% (placebo 0%)
acne 16.7% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence
20 mg
headache 33.3% (placebo 20%)
anogenital dysplasia 16.7% (placebo 0%)
conjunctivitis allergic 16.7% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence
Dose Level 1b
transaminases increased 16.7% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
arthralgia 0% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 16.7% (placebo 0%)
periodontitis 16.7% (placebo 0%)
rhinitis allergic 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
pyrexia 16.7% (placebo 0%)
thrombocytopenia 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
hypertriglyceridaemia 33.3% (placebo 0%)
cough 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
cough 16.7% (placebo 0%)
pharyngitis 16.7% (placebo 0%)
rhinitis 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
alanine aminotransferase increased 16.7% (placebo 0%)
dengue fever 16.7% (placebo 0%)
urticaria 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
900 mg
headache 16.7% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
450 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
450 mg
alanine aminotransferase increased 16.7% (placebo 10%)
amylase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
350 mg
alanine aminotransferase increased 16.7% (placebo 10%)
aspartate aminotransferase increased 16.7% (placebo 10%)
bile acids increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
250 mg + Midazolam
fatigue 62.5% (placebo 0%)
blood creatine phosphokinase increased 25% (placebo 0%)
low density lipoprotein increased 25% (placebo 0%)
NCT05163522 · Phase 1 · combination
150 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
100 mg
dyslipidaemia 33.3% (placebo 0%)
bile acids increased 16.7% (placebo 0%)
blood bilirubin increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
50 mg
abdominal discomfort 28.6% (placebo 0%)
diarrhoea 28.6% (placebo 0%)
body temperature increased 14.3% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
10 mg
chapped lips 16.7% (placebo 0%)
dermatitis contact 16.7% (placebo 10%)
dry mouth 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenacapavir (Sunlenca)

HIV-1 RNA Less Than 50 Copies 20% (n=5) vs 0% (n=10) placebo @ 1.4wk750 mg
responder rate · % of participants
NCT03739866 · Phase 1 · registry result, not featured evidence
show 16 more results
16.7% (n=6) vs 0% (n=10) placebo @ 1.4wk450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0% (n=6) vs 0% (n=10) placebo @ 1.4wk150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7% (n=6) vs 0% (n=10) placebo @ 1.4wk50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0% (n=6) vs 0% (n=10) placebo @ 1.4wk20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
90.4% (n=52) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
84.9% (n=53) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
84.6% (n=52) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
94.2% (n=52) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
92.5% (n=53) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
94.2% (n=52) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
90.4% (n=52) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
88.7% (n=53) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
88.5% (n=52) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
86.5% (n=52) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
75.5% (n=53) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
86.5% (n=52) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
HIV-1 RNA -2.26 vs -0.17 placebo log750 mg
absolute change · log
NCT03739866 · Phase 1 · registry result, not featured evidence
show 16 more results
-2.2 vs -0.17 placebo log450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.76 vs -0.17 placebo log150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.79 vs -0.17 placebo log50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.35 vs -0.17 placebo log20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-2.92 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-3.04 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-3.01 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-3.06 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-3.02 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-2.95 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-3.12 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-2.85 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
-3.08 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
CD4+ 172 vs 163 B/F/TAF cells/uL @ 28wk
absolute change · cells/uL
NCT04143594 · Phase 2 · combination
show 11 more results
158 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · combination
206 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · combination
195 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
220 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
211 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
204 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
213 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
220 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
275 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination
262 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination
245 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination

VH4004280 (VH-280)

HIV-1 RNA -1.056 vs -0.07 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.391 vs -0.07 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.983 vs -0.07 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -0.941 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.322 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.939 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenacapavir (Sunlenca)'s landscape · VH4004280 (VH-280)'s landscape